Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have earned an average rating of "Buy" from the fifteen analysts that are covering the stock, MarketBeat.com reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued a report on the stock in the last year is $216.73.

Several analysts recently issued reports on ASND shares. JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $200.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. The Goldman Sachs Group raised their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Bank of America raised their price target on Ascendis Pharma A/S from $196.00 to $201.00 and gave the stock a "buy" rating in a research note on Tuesday, June 3rd. Finally, Evercore ISI raised their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $173.06 on Friday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The business's 50-day moving average is $158.95 and its two-hundred day moving average is $146.64. The company has a market cap of $10.55 billion, a price-to-earnings ratio of -24.37 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ASND. Blue Trust Inc. grew its stake in Ascendis Pharma A/S by 540.5% during the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock worth $76,000 after buying an additional 427 shares during the last quarter. Legato Capital Management LLC lifted its holdings in shares of Ascendis Pharma A/S by 7.5% in the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after buying an additional 134 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $203,000. Rice Hall James & Associates LLC raised its holdings in Ascendis Pharma A/S by 2.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock worth $22,562,000 after purchasing an additional 3,274 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in Ascendis Pharma A/S by 14.0% in the 4th quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock worth $28,151,000 after purchasing an additional 25,164 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.